Patents by Inventor Michael S. Kinch

Michael S. Kinch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210198333
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Application
    Filed: August 19, 2020
    Publication date: July 1, 2021
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Walter J. Storkus, Michael S. Kinch
  • Patent number: 10781240
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 22, 2020
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Walter J. Storkus, Michael S. Kinch
  • Publication number: 20190023756
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Application
    Filed: October 4, 2018
    Publication date: January 24, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Walter J. Storkus, Michael S. Kinch
  • Patent number: 10131699
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: November 20, 2018
    Assignee: University Of Pittsburgh—Of the Commonwealth System Of Higher
    Inventors: Walter J. Storkus, Michael S. Kinch
  • Publication number: 20170002050
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopis are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Application
    Filed: June 3, 2016
    Publication date: January 5, 2017
    Applicant: University Of Pittsburgh - Of The Commonwealth System Of Higher Education
    Inventors: WALTER J. STORKUS, Michael S. Kinch
  • Patent number: 9359402
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: June 7, 2016
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Walter J. Storkus, Michael S. Kinch
  • Publication number: 20140271671
    Abstract: A method for identifying host genes and encoded proteins for potential targets for therapeutic intervention employs a Gene Search Vector that is either lentivirus or MMLV-based, and can be used to interrogate an entire cell genome without prior knowledge of the genomic sequence. This Random Homozygous Gene Perturbation (RUGP) technique is rapidly verifiable and is used to identify potential host targets for intervention for influenza, HIV and other viral infections. Using Thermal Assymetric Interlaced (TAIL)-PCR, the period for identification of promising targets is reduced from months to weeks or less. Specific targets including PTCH1, Robo1 and Nedd4 are reviewed in detail.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: Eli Lilly and Company
    Inventors: Michael S. Kinch, Michael Goldblatt, Wu-Bo Li, Douty Bamba, Shaojing Chang, Huosheng Chen, Zenbework Fesseha, Manu Kohli, Hanwen Mao, Heather Thi Thu Ung-Medoff, Ke Weng
  • Publication number: 20140134198
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Application
    Filed: October 31, 2013
    Publication date: May 15, 2014
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Walter J. Storkus, Michael S. Kinch
  • Patent number: 8591887
    Abstract: The present invention is directed to compounds and methods for the treatment of metastatic disease. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. The compounds used in accordance with this invention may be provided in a pharmaceutical composition for treatment of metastatic disease.
    Type: Grant
    Filed: January 7, 2010
    Date of Patent: November 26, 2013
    Assignee: Purdue Research Foundation
    Inventors: Michael S. Kinch, Nicole D. Zantek, Patrick W. Hein
  • Patent number: 8535684
    Abstract: A method for identifying host genes and encoded proteins for potential targets for therapeutic intervention employs a Gene Search Vector that is either lentivirus or MMLV-based, and can be used to interrogate an entire cell genome without prior knowledge of the genomic sequence. This Random Homozygous Gene Perturbation (RUGP) technique is rapidly verifiable and is used to identify potential host targets for intervention for influenza, HIV and other viral infections. Using Thermal Assymetric Interlaced (TAIL)-PCR, the period for identification of promising targets is reduced from months to weeks or less. Specific targets including PTCH1, Robo1 and Nedd4 are reviewed in detail.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: September 17, 2013
    Assignee: Functional Genetics, Inc.
    Inventors: Michael S. Kinch, Michael Goldblatt, Wu-Bo Li, Douty Bamba, Shaojing Chang, Huosheng Chen, Zenbework Fesseha, Manu Kohli, Hanwen Mao, Heather Thi Thu Ung-Medoff, Ke Weng
  • Publication number: 20120201840
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Application
    Filed: January 20, 2012
    Publication date: August 9, 2012
    Inventors: Walter J. Storkus, Michael S. Kinch
  • Publication number: 20120122112
    Abstract: Method and kits are provided for the detection and diagnosis of metastatic disease. More particularly, the methods and kits employ compounds that can detect EphA2, a specific epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. In one embodiment the compound is an antibody capable of binding to an epitope of EphA2.
    Type: Application
    Filed: August 16, 2011
    Publication date: May 17, 2012
    Applicant: Purdue Research Foundation
    Inventors: Michael S. KINCH, Nicole D. Zantek
  • Publication number: 20120121582
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of non-neoplastic hyperproliferative epithelial and/or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and/or aberrant angiogenesis. Non-limiting examples of such disorders include cirrhosis, fibrosis (e.g.
    Type: Application
    Filed: January 26, 2011
    Publication date: May 17, 2012
    Applicant: Medimmune, LLC
    Inventors: Michael S. Kinch, Kelly Carles-Kinch
  • Patent number: 8114407
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Grant
    Filed: October 22, 2007
    Date of Patent: February 14, 2012
    Inventors: Walter J. Storkus, Michael S. Kinch
  • Publication number: 20110280892
    Abstract: The present invention relates to compositions and methods for inducing cell death or stasis in cancer cells or other hyperproliferative cells using anti-EphA2 or anti-EphA4 antibodies conjugated to toxins.
    Type: Application
    Filed: December 21, 2010
    Publication date: November 17, 2011
    Applicants: MedImmune, LLC, Seattle Genetics, Inc.
    Inventors: Michael S. Kinch, Herren Wu, Christine Bachy, David Tice, Changshou Gao, Peter D. Senter
  • Publication number: 20110150898
    Abstract: The present invention is directed to compounds and methods for the treatment of metastatic disease. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. The compounds used in accordance with this invention may be provided in a pharmaceutical composition for treatment of metastatic disease.
    Type: Application
    Filed: January 7, 2010
    Publication date: June 23, 2011
    Applicant: Purdue Research Foundation
    Inventors: Michael S. Kinch, Nicole D. Zantek, Patrick W. Hein
  • Publication number: 20110053182
    Abstract: The present invention relates to methods and compositions designed for the treatment or management of pre-cancerous conditions, especially in order to prevent, delay, or decrease the likelihood that the pre-cancerous condition will progress to malignant cancer. The methods of the invention comprise the administration of an effective amount of one or more agents that decrease/inhibit PCDGF expression, secretion, and/or activity. The invention also provides pharmaceutical compositions comprising one or more PCDGF agents. In some embodiments, the PCDGF agents can be administered with other therapeutic agents for treatment or management of a pre-cancerous condition that are not PCDGF-based. Diagnostic methods and methods for screening for therapeutically useful PCDGF agents are also provided.
    Type: Application
    Filed: November 5, 2009
    Publication date: March 3, 2011
    Inventors: MICHAEL S. KINCH, GINETTE SERRERO
  • Publication number: 20100298545
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: November 25, 2009
    Publication date: November 25, 2010
    Inventors: Michael S. Kinch, Kelly Carles-Kinch, Jane c. Stewart
  • Publication number: 20100278838
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low Koff, thereby, inhibiting tumor cell growth and/or metastasis.
    Type: Application
    Filed: April 7, 2010
    Publication date: November 4, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: Michael S. Kinch, Kelly Carles-Kinch, Peter Kiener, Solomon Langermann
  • Publication number: 20100260749
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of non-neoplastic hyperproliferative epithelial and/or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and/or aberrant angiogenesis. Non-limiting examples of such disorders include cirrhosis, fibrosis (e.g.
    Type: Application
    Filed: August 4, 2008
    Publication date: October 14, 2010
    Applicant: MEDIMMUNE, INC.
    Inventors: Michael S. Kinch, Kelly Carles-Kinch